Americord announced today that it has provided funding to MEDIPOST , a leading stem cell biotechnology company, to support their clinical trial investigating the use of NEUROSTEM-AD in the treatment of patients with Alzheimer's Disease.
http://ift.tt/1hsgcAn
http://ift.tt/1hsgcAn
No comments:
Post a Comment